Gilead, BMS, Janssen facing HIV generic antitrust suit

16-12-2021

Muireann Bolger

Gilead, BMS, Janssen facing HIV generic antitrust suit

Sundry Photography / Shutterstock.com

Gilead, Bristol-Myers Squibb and Janssen are facing accusations that they suppressed competition in the market for drugs used to treat the human immunodeficiency virus (HIV).


Gilead, Teva, BMS, Janssen, generics

LSIPR